bioRxiv Science⌕ Search

bioRxiv · 10.1101/654939

An ancestral informative marker panel design for individual ancestry estimation of Hispanic population using whole exome sequencing data

Abstract

BackgroundEuropeans and American Indians were major genetic ancestry of Hispanics in the U.S. In those ancestral groups, it has markedly different incidence rates and outcomes in many types of cancers. Therefore, the genetic admixture may cause biased genetic association study with cancer susceptibility variants specifically in Hispanics. The incidence rate and genetic mutational pattern of liver cancer have been shown substantial disparity between Hispanic, Asian and non-Hispanic white populations. Currently, ancestry informative marker (AIM) panels have been widely utilized with up to a few hundred ancestry-informative single nucleotide polymorphisms (SNPs) to infer ancestry admixture. Notably, current available AIMs are predominantly located in intron and intergenic regions, while the whole exome sequencing (WES) protocols commonly used in translational research and clinical practice do not contain these markers, thus, the challenge to accurately determine a patients admixture proportion without subject to additional DNA testing.\n\nMethodsHere we designed a bioinformatics pipeline to obtain an AIM panel. The panel infers 3-way genetic admixture from three distinct continental populations (African (AFR), European (EUR), and East Asian (EAS)) constraint within evolutionary-conserved exome regions. Briefly, we extract [~]1 million exonic SNPs from all individuals of three populations in the 1000 Genomes Project. Then, the SNPs were trimmed by their linkage disequilibrium (LD), restricted to biallelic variants only, and assembled as an AIM panel with the top ancestral informativeness statistics based on the In-statistic. The selected AIM panel was applied to training dataset and clinical dataset. Finally, The ancestral proportions of each individual was estimated by STRUCTURE.\n\nResultsIn this study, the optimally selected AIM panel with 250 markers, or the UT-AIM250 panel, was performed with better accuracy as one of the published AIM panels when we tested with 3 ancestral populations (Accuracy: 0.995 {+/-} 0.012 for AFR, 0.997 {+/-} 0.007 for EUR, and 0.994 {+/-} 0.012 for EAS). We demonstrated the utility of UT-AIM250 panel on the admixed American (AMR) of the 1000 Genomes Project and obtained similar results (AFR: 0.085 {+/-} 0.098; EUR: 0.665 {+/-} 0.182; and EAS 0.250 {+/-} 0.205) to previously published AIM panels (Phillips-AIM34: AFR: 0.096 {+/-} 0.127, EUR: 0.575 {+/-} 0.29; and EAS: 0.330 {+/-} 0.315; Wei-AIM278: AFR: 0.070 {+/-} 0.096, EUR: 0.537 {+/-} 0.267, and EAS: 0.393 {+/-} 0.300) with no significant difference (Pearson correlation, P < 10-50, n = 347 samples). Subsequently, we applied UT-AIM250 panel to clinical datasets of self-reported Hispanic patients in South Texas with hepatocellular carcinoma (26 patients). Our estimated admixture proportions from adjacent non-cancer liver tissue data of Hispanics in South Texas is (AFR: 0.065 {+/-} 0.043; EUR: 0.594 {+/-} 0.150; and EAS: 0.341 {+/-} 0.160), with smaller variation due to its unique Texan/Mexican American population in South Texas. Similar admixture proportion from the corresponding tumor tissue we also obtained. In addition, we estimated admixture proportions of entire TCGA-LIHC samples (376 patients) using UT-AIM250 panel. We demonstrated that our AIM panel estimate consistent admixture proportions from DNAs derived from tumor and normal tissues, and 2 possible incorrect reported race/ethnicity, and/or provide race/ethnicity determination if necessary.\n\nConclusionsTaken together, we demonstrated the feasibility of using evolutionary-conserved exome regions to distinguish genetic ancestry descendants based on 3 continental-ancestry proportion, provided a robust and reliable control for sample collection or patient stratification for genetic analysis. R implementation of UT-AIM250 is available at https://github.com/chenlabgccri/UT-AIM250.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wang, L.-J., Zhang, C. W., Su, S. C., Chen, H.-I. H., Chiu, Y.-C., Lai, Z., Bouamar, H., Ramirez, A. G., Cigarroa, F. G., Sun, L.-Z., Chen, Y.. 2019-05-31. An ancestral informative marker panel design for individual ancestry estimation of Hispanic population using whole exome sequencing data. https://doi.org/10.1101/654939

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Classifying tumors from broad category to hierarchical molecular subtype: an interpretable hierarchical framework for precision oncology

Precise tumor subtype classification is important for guiding personalized treatment, characterizing tumor heterogeneity, and investigating molecular mechanisms. However, most existing multi-label classification models use flat architectures and do not fully exploit the inherent hierarchical relationships and biological constraints among tumor types, which limits their performance and interpretability in complex, fine-grained pan-cancer classification. Here, we present the cancer Hallmark-based Hierarchical Recursive Model (HHRM) for pan-cancer hierarchical multi-label classification. HHRM integrates hierarchical label structures with recursive neural networks, enabling simultaneous modeling of multi-level dependencies from broad cancer categories to specific subtypes. We trained the model on a comprehensive pan-cancer cohort of 11,476 samples spanning 26 primary cancer types and 405 subtypes across up to eight hierarchical levels. HHRM achieved an accuracy of 0.7924 for predicting hierarchical tumor subtypes and was further evaluated on a validation dataset of 887 samples. Compared with other hierarchical modeling frameworks, HHRM achieved higher accuracy in all three output modes. Ablation experiments showed that replacing the hallmark-based graph convolutional network reduced model performance. On an independent dataset of 1,608 breast cancer samples, HHRM also achieved an accuracy greater than 0.86. Finally, we combined SHAP with a network-based method to rank and analyze predictive genes at different levels of the tumor hierarchy, which identified both known and potentially novel biomarkers for cancer diagnosis. In conclusion, to our knowledge, HHRM is the first hierarchical model for multi-level tumor subtype classification. Its competitive performance, combined with post hoc biological interpretation, suggests potential value for precision cancer diagnosis.

bioinformatics↗

A comparative transcriptomic framework across kidney organoid, assembloid, and transplantation models

Human kidney organoids recapitulate key aspects of renal development and have emerged as valuable platforms for disease modeling, nephrotoxicity screening, and therapeutic development. The field now includes a wide range of emerging protocols with distinct cellular compositions and maturation states, which complicates systematic comparison and model selection. Here, we integrated single-cell and single-nucleus transcriptomes from 11 studies spanning kidney organoid and assembloids, both in vitro and following transplantation, benchmarked against fetal and adult kidney references. Transcriptional maturation toward adult identity is compartment specific and does not correlate with protocol complexity. Assembloid protocols show the most adult-like podocyte and distal nephron signatures, transplantation is associated with enhanced tubular oxidative metabolic features, only protocols incorporating ureteric progenitors reliably generate collecting-duct lineages, and no protocol achieves mature adult proximal tubule identity. Annotating against either fetal or adult kidney reference alone leads to misassignment, because early fetal nephron epithelium transcriptionally resembles injury-dedifferentiated adult proximal tubule cells. Assembloid and transplantation models share elevated mechanosensing pathway expression independently of vascularization. Together, these findings provide a framework for kidney organoid model selection.

bioinformatics↗

OncoSpot enables benchmarking of cancer spatial transcriptomics methods across tumor evolutionary modes

Spatial transcriptomics (ST) is increasingly used to map clonal architecture within tumors, yet methods for analyzing cancer ST data are difficult to evaluate because real tumors lack ground truth for copy-number alterations (CNAs), subclonal identity, and malignant cell fraction. Existing ST simulators model normal tissue and do not represent tumor evolution, CNA-driven expression, or the spatial organization of malignant subclones. We present OncoSpot, a cancer-aware simulator of Visium-like spot-based ST data. OncoSpot combines a spatial evolutionary scaffold from DEMON, CNAs generated along the resulting clonal phylogeny with CNAsim, cancer-type-specific malignant transcriptional programs, and spatially clustered nonmalignant cell types, and aggregates cells into spots with known malignant fraction, subclone, and copy-number profiles. We demonstrate OncoSpot on high-grade serous ovarian carcinoma, colorectal cancer, and hepatocellular carcinoma, which represent three distinct modes of tumor evolution. Simulated subclones were spatially clustered and showed stronger phylogeny-space concordance than those generated by scCube under matched subclone populations. Benchmarking CopyKAT, CancerFinder, Clonalscope, and RCTD revealed cancer-dependent performance: Clonalscope recovered copy-number signals more accurately in ovarian and colorectal cancer, whereas CopyKAT performed better in hepatocellular carcinoma, reflecting both the assumptions of each method and the copy-number landscapes of the three cancers. OncoSpot's ground truth also exposed a failure mode in Clonalscope's malignant spot identification, in which tumor and normal labels were inverted, and allowed us to trace its cause. These method-dependent behaviors would be difficult to detect in real data. OncoSpot provides a framework for benchmarking CNA inference, subclone detection, malignant spot identification, and normal spot deconvolution, and its modular design and guidelines allow extension to additional cancer types. OncoSpot is freely available at https://github.com/compbio-mallory/OncoSpot.

bioinformatics↗